Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Business Wire•05/10/2026•16:05 ET
0
Key Highlights
- ➤Vir to present expanded Phase 2 SOLSTICE results for elebsiran and tobevibart
- ➤SOLSTICE efficacy data will detail HDV RNA responses through Week 96
- ➤Translational sub-study will examine intrahepatic NK cell remodeling in chronic hepatitis D
- ➤Presentations scheduled November 8, 2026, at AASLD’s The Liver Meeting
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting(® )2026
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(®) 2026 in Denver, CO, November 5-9, 2026.
Get started
Create a free account to read the full story.